Scinai Immunotherapeutics (SCNI) Income from Continuing Operations (2014 - 2024)

Scinai Immunotherapeutics has disclosed Income from Continuing Operations across 11 years of filings, most recently posting 2263000.0 for Q4 2024.

• Income from Continuing Operations for Q4 2024 came in at 2263000.0, down 24.14% year-over-year; the trailing twelve-month figure through Dec 2024 was 4736000.0 (up 241.25% YoY), and the FY2025 annual result was 9745000.0, down 12.82% from the prior year.
• Income from Continuing Operations came in at 2263000.0 for Q4 2024 at Scinai Immunotherapeutics, down from 10954000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 55891000.0 in Q3 2020 to a low of 19901000.0 in Q1 2020.
• The 5-year median for Income from Continuing Operations is 1823000.0 (2023), against an average of 779736.84.
• Across the five-year window, Income from Continuing Operations jumped 405.05% in 2020 and sank 1755.58% in 2023, its largest moves.
• Scinai Immunotherapeutics' Income from Continuing Operations stood at 11360000.0 in 2020, then surged by 238.61% to 15746000.0 in 2021, then tumbled by 221.3% to 19100000.0 in 2022, then surged by 90.46% to 1823000.0 in 2023, then retreated by 24.14% to 2263000.0 in 2024.
• The last three Income from Continuing Operations figures came in at 2263000.0 (Q4 2024), 10954000.0 (Q3 2024), and 5883000.0 (Q2 2024), per Business Quant data.